$9.3MSeries A, 3 March 2026
Funds its antibody pipeline; also signed a research deal with the Cystic Fibrosis Foundation.
- Amount
- $9.3M
- Stage
- Series A
- Announced
- 3 March 2026
- Lead
- Soulmates Ventures
- Other investors
- Development Bank of Wales
- Use of funds
- Funds its antibody pipeline; also signed a research deal with the Cystic Fibrosis Foundation.
- Checked
- Announced by the company
- Source
- Antiverse secures £7M ($9.3M) Series A uktechnews.info